IGI INC
10-Q, EX-27.1, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: IGI INC, 10-Q, EX-10.3, 2000-11-14
Next: IGI INC, 10-Q, EX-27.2, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                             168
<SECURITIES>                                         0
<RECEIVABLES>                                    2,273
<ALLOWANCES>                                       259
<INVENTORY>                                      3,024
<CURRENT-ASSETS>                                 6,908
<PP&E>                                          10,574
<DEPRECIATION>                                 (5,119)
<TOTAL-ASSETS>                                  13,441
<CURRENT-LIABILITIES>                           15,159
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           103
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                    13,441
<SALES>                                         12,735
<TOTAL-REVENUES>                                14,792
<CGS>                                            7,968
<TOTAL-COSTS>                                    7,493
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               2,220
<INCOME-PRETAX>                                (2,889)
<INCOME-TAX>                                     5,852
<INCOME-CONTINUING>                            (8,741)
<DISCONTINUED>                                 (1,583)
<EXTRAORDINARY>                                  (984)
<CHANGES>                                            0
<NET-INCOME>                                  (11,308)
<EPS-BASIC>                                     (1.11)
<EPS-DILUTED>                                   (1.11)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission